Dr. Wu Skincare Co,. Ltd. has reported a net profit of NT$480 million for 2024, benefiting from both favorable foreign exchange gains and strong core business growth. This translates to an earnings per share (EPS) of NT$10.57, surpassing one share’s par value. The company’s board has approved a fourth-quarter cash dividend of NT$2 per share, bringing the total annual dividend payout to NT$11 per share.
Dr. Wu Skincare achieved a record-breaking consolidated revenue of NT$1.24 billion in 2024, marking a 9% year-over-year increase. Effective cost and expense management allowed the company to maintain a gross margin of 71% and an operating margin of 42%, solidifying its position as a leading player in the medical skincare industry.
Analysts predict that Dr. Wu Skincare’s overseas market adjustments will yield positive contributions in 2025. The Japanese market, a key revenue driver, is expected to regain growth momentum, supported by an expanded product lineup within its flagship mandelic acid skincare range. Meanwhile, Southeast Asian markets, particularly Singapore and Malaysia, are poised for steady expansion.
In Taiwan, Dr. Wu Skincare plans to maintain its product renewal cycle at 15% annually, ensuring a constantly refreshed product portfolio to sustain consumer interest. This strategy is expected to support continued growth, with the company projecting at least high-single-digit revenue expansion for 2025.
Resource: 達爾膚去年EPS 10.57元 配發第四季現金股利2元
